Skye Bioscience, Inc. Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration
Skye Bioscience, Inc. (SKYE) had Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration of $13.21 million as of 2020-12-31, per its 10-K filed 2021-03-02.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration · last filed 2021-03-02
- 2020-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $13.21M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration |
|---|---|
| 2020-12-31 | $13.21M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |